874375-75-4Relevant academic research and scientific papers
Discovery of a cyclopentylamine as an orally active dual NK1 receptor antagonist-serotonin reuptake transporter inhibitor
Wu, Yong-Jin,He, Huan,Gao, Qi,Wu, Dedong,Bertekap, Robert,Westphal, Ryan S.,Lelas, Snjezana,Newton, Amy,Wallace, Tanya,Taber, Matthew,Davis, Carl,Macor, John E.,Bronson, Joanne
, p. 1611 - 1614 (2014/03/21)
Cyclopentylamine 4 was identified as a potent dual NK1R antagonist-SERT inhibitor. This compound demonstrated significant oral activity in the gerbil forced swimming test, suggesting that dual NK1R antagonists-SERT inhibitors may be
Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists
-
Page/Page column 11; 12, (2010/02/15)
The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.
